GPX4 suppression, alone or with current TNBC therapies, impacts outcomes in preclinical TNBC models with or without obesity and offers a new, plausible mechanistic target for TNBC treatment. Here, GPX4 is linked to obesity due to melanocortin 4 receptor deficiency.